What Happened?
Shares of healthcare tech company GoodRx (NASDAQ: GDRX) jumped 2.6% in the afternoon session after the company announced a partnership with Paytient, a healthcare affordability solutions provider.
The collaboration aims to make it easier for employees to pay less for prescription drugs. Paytient, which works with employers, will directly embed GoodRx's platform to offer lower cash-pay prices on medications. This integration pairs GoodRx's prescription savings, available at over 70,000 U.S. pharmacies, with Paytient's flexible payment methods. For GoodRx, this partnership expands its reach into the employer-sponsored benefits market, potentially increasing its user base and reinforcing its position as a leading platform for prescription savings.
After the initial pop, the shares cooled down to $3.01, up 1.9% from the previous close.
Is now the time to buy GoodRx? Access our full analysis report here, it’s free.
What Is The Market Telling Us
GoodRx’s shares are extremely volatile and have had 35 moves greater than 5% over the last year. In that context, today’s move indicates the market considers this news meaningful but not something that would fundamentally change its perception of the business.
The biggest move we wrote about over the last year was 11 months ago when the stock gained 40.2% on the news that the company announced a collaboration with pharmaceutical giant Novo Nordisk to offer the popular medications Ozempic and Wegovy for $499 per month to eligible self-paying customers.
This landmark collaboration makes the popular GLP-1 medications—used for type 2 diabetes (Ozempic) and weight loss (Wegovy)—available at a significantly lower cost to those who lack adequate insurance coverage. According to the announcement, this marks the first time Ozempic has been offered at this self-pay price point.
The offer is effective immediately and available through the GoodRx platform at over 70,000 retail pharmacies nationwide. Investors reacted positively, viewing the strategic partnership as a pivotal move that could substantially expand GoodRx's market reach and user base by capitalizing on the high-demand therapeutic category.
GoodRx is up 9.3% since the beginning of the year, but at $3.01 per share, it is still trading 41.3% below its 52-week high of $5.12 from August 2025. Despite the year-to-date gain, investors who bought $1,000 worth of GoodRx’s shares 5 years ago would now be looking at only $96.07.
ONE MORE THING: 3 Hidden Platforms Growing 3X Faster than Amazon, Google, and PayPal. Amazon, Google, and Meta all followed the same playbook: Dominate an ignored market. Build an unbeatable moat. Scale until you’re unstoppable.
These three platforms are running that exact playbook right now. The early investors in Amazon made fortunes. The early investors in these could do the same. Get All 3 Stocks Here for FREE.
